Table 2.
All PD (n = 72) | Left-onset PD (n = 27) | Right-onset PD (n = 45) | Non-PD (n = 48) | |
---|---|---|---|---|
Age | 67.75 ± 5.86 | 67.19 ± 5.01 | 68.09 ± 6.34 | 68.17 ± 4.97 |
Education | 16.28 ± 2.67 | 16.33 ± 2.29 | 16.24 ± 2.89 | 16.89 ± 2.24 |
Sex (M:F) | 51:21 | 19:8 | 32:13 | 38:10 |
Disease duration | 7.00 ± 4.98 | 5.37 ± 3.10** | 7.98 ± 5.63** | – |
MMSE | 28.59 ± 1.33* | 28.59 ± 1.34 | 28.58 ± 1.31 | 29.26 ± 0.94* |
WTAR estimated IQ | 109.46 ± 7.34 | 109.52 ± 6.92 | 109.40 ± 7.76 | 109.64 ± 8.41 |
UPDRS part 3 | 18.04 ± 10.09* | 17.74 ± 8.83 | 18.28 ± 10.92 | 2.96 ± 3.57* |
LED | 585.07 ± 334.34* | 539.00 ± 232.69 | 631.13 ± 435.99 | 0.85 ± 5.83*,a |
UPDRS part 3 is the motor symptom scale of the United PD Rating Scale; LED, Levodopa equivalence score; MMSE, mini-mental state examination; WTAR, Wechsler Test of Adult Reading.
aOne non-PD participant was taking levodopa for restless leg syndrome.
*Indicates significant PD/non-PD difference, p < 0.05.
**Indicates significant L-PD/R-PD difference, p < 0.05.